← All trials
NCT06954428
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 20, 2025
- Primary completion
- Oct 28, 2025
- Completion date
- Dec 28, 2025
- First posted
- May 1, 2025
- Last posted
- Jul 29, 2025
- Enrollment
- 48
- Arms / groups
- 8 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Nano PharmaSolutionsLead sponsor
- Beyond Drug DevelopmentCollaborator
- CMAX Clinical ResearchCollaborator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.